PolyActiva

🚨 PolyActiva's CEO, Vanessa Waddell, and our Head of Product Development & Technical Affairs, Justine Walter, will both be attending AusBiotech 2024 starting tomorrow at Melbourne's Convention & Exhibition Centre. With so many incredible industry leaders and experts attending, we can't wait to see what the next few days has in store for us! If you're in the area and would like to catch up with our team, reach out and say hello 👋 We'd love to fill you in on what we've been up to! #Ausbiotech2024 #Innovation #Biotech #Investment

PolyActiva is excited to announce that our CEO, Vanessa Waddell, will be presenting at #AusBioInvest24 on 29 October in the 4:00pm – 4:55pm session. Vanessa will be presenting our latest 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of repeat-dosing with our PA5108 Ocular Implant, and sustained reduction in intraocular pressure in this repeat-dose cohort out to 48 weeks. This data backs our goal of providing patients suffering from glaucoma a long-term sustained-release alternative solution to drop therapy. Thank you AusBiotech for this opportunity, we can’t wait to share these results with you and what we have on the horizon. #AusBio #AusBioInv24 #Glaucoma #Innovation

We're incredibly proud of our CEO Vanessa Waddell's recent presentation at Eyecelerator @ AAO2024 last week. Vanessa got the chance to present our new 48-week clinical data from our Phase 1b/2a clinical trial, which demonstrates both the safety of our PA5108 after repeat-dosing, as well as a sustained reduction in intraocular pressure out to 48 weeks. These results are the culmination of over a decade of research and work by our incredible team, with help from countless other consultants and clinicians along the way. It's exciting to be another step closer to providing patients suffering from glaucoma a safe and effective sustained-release implant as an alternative to drop therapy! #Glaucoma #Biotech #Innovation #AAO2024

PolyActiva's Nonclinical & Formulation Leader Dr. Igor Chekhtman, and Commercial Operations & BD Associate Alexander Goulsbra attended the BioConnections 2024 Conference last week. Thank you to Informa Australia for putting together such an insightful conference with incredible keynote speakers and excellent panel discussions! It was also great to catch up with Camille Shanahan from Jumar Bioincubator, where PolyActiva is utilising their state-of-the-art laboratories to continue manufacturing our ocular implants locally, ready for our upcoming clinical trial program. #BioConnexAus #Glaucoma #Innovation #Incubator #Biotech

The PolyActiva Polymer Chemistry Team has had a busy week setting up the cleanrooms at Jumar in Melbourne so we can keep the manufacture of our phase 1 clinical trial material local. With limited options for manufacturing our ocular implants, access to Jumar’s state-of-the-art laboratories provides us with the opportunity to build our ocular implant manufacturing capabilities internally rather than having to go offshore. It’s an exciting time, and we’re also looking forward to joining a community fostering the next generation of Australian biotech

PolyActiva's Head of Polymers & Medical Devices, Dr. David Valade will be presenting at PharmOut's Pharma & Device Forum 2024 this Friday 24 May at the Melbourne Exhibition and Convention Centre in Melbourne, Australia. David will be discussing the hurdles PolyActiva has overcome to manufacture our unique sustained-release, biodegradable ocular implants for use in our clinical trial programs. If you're attending this event, you can catch David's presentation in Room 103 from 2:00pm - 2:30pm AEST. Come and say hi! #Glaucoma #Pharmaceutical #Manufacturing #Innovation

PolyActiva wishes to congratulate Michelle McIntosh on her success and the well-deserved recognition as the winner of the BioMelbourne Network 2024 Inspiring Leadership Award. We have had the pleasure of working with Michelle and the team at the Medicines Manufacturing Innovation Centre - MMIC, Monash University since 2016 to characterise and test our ocular implants. Thank you to BioMelbourne Network and their sponsors for having us at the 2024 Connecting Women Lunch! It was an incredible event, and a great opportunity to connect with so many peers in the biotech and healthcare industry. #biomelbwomen #biotechnology #innovation

PolyActiva's Head of Chemistry, Pipeline Innovation and IP Dr. Andrew Donohue, along with our Nonclinical and Formulation Leader Dr. Igor Chekhtman had the chance to spend the past few days at the #ARVO2024 Annual Meeting in Seattle, USA. During their time there, Andrew and Igor gained valuable insight into new opportunities for sustained drug delivery in ophthalmology, which is integral as we look forward and progress our lead program into Phase 2 clinical trials later this year. Thank you to the Association for Research in Vision and Ophthalmology (ARVO) for hosting such an excellent event! #Glaucoma #Innovation #DrugDelivery #Ophthalmology #Biotechnology

PolyActiva is pleased to announce it has been awarded a $1.5m CUREator Grant, made available through the Federal Government’s Medical Research Future Fund’s Early-Stage Translation and Commercialisation Support (ESTAC) funding. With this funding, PolyActiva will complete a Phase 1 clinical trial in Australia of PA5346, its second-generation latanoprost-releasing ocular implant designed to deliver 12 months of treatment for patients with glaucoma. PolyActiva’s unique and differentiated Prezia™ drug delivery platform is used to develop injectable ocular implants to treat various ophthalmic conditions. PolyActiva’s first-generation lead product (PA5108) is demonstrating promising results in phase 2 clinical trials targeting 6 months of therapy. PolyActiva’s second-generation product, PA5346, is a small biodegradable rod that is expected to deliver a sustained daily dose of latanoprost to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension over 12 months. “We are delighted to be the recipient of a CUREator Grant for the development of PA5346, which provides us with the opportunity to pursue development of a second clinical candidate in our pipeline of glaucoma treatments. Early data with PA5346 suggests it has the potential to provide 12 months treatment for patients with glaucoma. The CUREator Grant will allow us to determine if this product truly meets that objective” says Vanessa Waddell, CEO of PolyActiva. “Because PolyActiva’s implants rapidly biodegrade at the end of the treatment period, we believe that they will be able to be given repeatedly, and that would change the way we manage this eye disease.” Read the full statement here: https://lnkd.in/emSYKvkT #Glaucoma #DrugDelivery #CUREator #Biotechnology #Innovation 

Thank you to the Australian Investment Council for sharing the video case study on PolyActiva by the Department of Industry, Science and Resources! This case study highlights the importance of collaboration between Australian Government and Venture Capital groups to enhance funding for Australian #Biotechnology and #Biomedical companies to progress the amazing work that is happening in this industry, translating ideas into #innovative products that can benefit society. PolyActiva is continuing to progress a sustained-release biodegradable ocular implant for the treatment of glaucoma, and we look forward to sharing updates related to our programs in the coming months. #Glaucoma #Innovation #VentureCapital #MedTech